Sign in
4

Changes in Ownership

Protalix BioTherapeutics, Inc. Filed Acc 0001144204-15-028480

Options or other derivatives

  • SVP, Product Development acquired 250,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Almon Einat Brill SVP, Product Development 2015-03-23 Grant or award · Stock Options (Right to Buy) +250,000 250,000 D
Loading xslF345X03/v409796_4.xml…